Skip to main content
For Canadian healthcare professionals only

References

  1. INSPIOLTO® RESPIMAT® Product Monograph. Boehringer Ingelheim (Canada) Ltd., November 14, 2019.

  2. SPIRIVA® RESPIMAT® Product Monograph. Boehringer Ingelheim (Canada) Ltd., May 7, 2019.

  3. COMBIVENT® RESPIMAT® Product Monograph. Boehringer Ingelheim (Canada) Ltd., November 7, 2019.

  4. Bourbeau J, et al. 2023 Canadian Thoracic Society Clinical Guideline on Pharmacotherapy in Patients with Stable COPD. Can Resp J 2023;7(4):173–91.

  5. Dalby R, et al. A review of the development of Respimat® Soft MistTM Inhaler. Int J Pharm 2004;283:1–9.

  6. Ipsos Healthcare. Respimat Patient Experience Survey. October 26, 2016.

  7. Data on File. Use Licensing Agreement. February 1, 2019.

  8. Data on File. Inspiolto. April 5, 2023.

  9. Buhl R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J 2015;45(4):969–79.

  10. Data on File. April 23, 2014.

  11. Data on File. April 25, 2014.

  12. O’Donnell DE, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J 2017;49(4):1601348.

  13. Beeh K-M, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J COPD 2016;11:193–205.

  14. Data on File. June 20, 2019.

  15. Maltais F, et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2018;12:1–13.

  16. Troosters T, et al. Effect of bronchodilation and exercise training with behavior modification on exercise tolerance and downstream effects on symptoms and physical activity in COPD. Am J Respir Crit Care Med 2018;198(8):1021–32.

  17. Calverley P, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomized, parallel-group, active-controlled trial. Lancet Resp Med 2018;6(5):337–44.

  18. Maltais F, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Resp J 2019;53:1—11.

  19. PrTUDORZA® GENUAIR® Product Monograph. AstraZeneca Canada Inc., June 4, 2018.

  20. PrSEEBRI® BREEZHALER® Product Monograph. Novartis Pharmaeuticals Canada Inc., September 29, 2016.

  21. SPIRIVA® HandiHaler® Product Monograph. Boehringer Ingelheim (Canada) Ltd., April 22, 2022.

  22. PrINCRUSE ELLIPTA Product Monograph. GlaxoSmithKline Inc., June 4, 2018.

  23. Data on File. Spiriva. April 5, 2023.

  24. Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide for COPD Diagnosis, Management and Prevention (2023 Report). Accessed: March 28, 2022. Available at: https://goldcopd.org/2023-gold-report-2/.

  25. Nici L, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Resp Crit Care Med 2020;201(9):e56–e69.

  26. Alberta Health. Drug Benefit List - INSPIOLTO RESPIMAT. Accessed: February 25, 2025. Available at: https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=66327365-71d5-40dd-b51d-d901a322bc5d&id=0000075187&intchg_grp_nbr=1&detailId=13581414.

  27. Alberta Blue Cross. Long-Acting Fixed-Dose Combination Products for Asthma/COPD SPECIAL AUTHORIZATION REQUEST FORM. Accessed: October 21, 2020. Available at: https://www.ab.bluecross.ca/dbl/pdfs/60025.pdf.

  28. Alberta Health. Drug Benefit List - SPIRIVA RESPIMAT. Accessed: October 21, 2020. Available at: https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=8f02f66e-969f-40e4-ac58-c8b4b90d72c4&id=0000072885&intchg_grp_nbr=1&detailId=2902981.

  29. Alberta Health. Drug Benefit List - COMBIVENT RESPIMAT. Accessed: December 15, 2020. Available at: https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=3ce733e2-01a7-40a7-8870-441cfe2dd704&id=0000071265&intchg_grp_nbr=1&detailId=3237250.

  30. BC PharmaCare – Inspiolto Respimat. Accessed: October 21, 2020. Available at: https://pharmacareformularysearch.gov.bc.ca/Search.xhtml.

  31. BC PharmaCare. Limited Coverage Drug (LCD) Program. Accessed: August 9, 2022. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drugs-tiotropium-olodaterol.

  32. BC PharmaCare – Spiriva Respimat. Accessed: October 21, 2020. Available at: https://pharmacareformularysearch.gov.bc.ca/Search.xhtml.

  33. BC PharmaCare – Combivent Respimat. Accessed: December 15, 2020. Available at: https://pharmacareformularysearch.gov.bc.ca/Search.xhtml.

  34. Government of Manitoba. Part 3 Exceptional Drug Status (EDS). Accessed: October 21, 2020. Available at: https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf.

  35. Manitoba Drug Formulary – Combivent Respimat. Accessed: September 7, 2021. Available at:
     https://web22.gov.mb.ca/eFormulary/searchResults.aspx?query=COMBIVENT RESPIMAT&type=basic.

  36. New Brunswick Drug Plans Formulary October 2020. Accessed: October 21, 2020. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/hs/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf .

  37. New Brunswick Drug Plan Overview June 2022. Accessed: June 30, 2022. Available at: https://www2.gnb.ca/content/gnb/en/departments/health/MedicarePrescriptionDrugPlan/NBDrugPlan/ForHealthCareProfessionals/NewBrunswickDrugPlansFormulary.html.

  38. NLPDP Drug Product Database – INSPIOLTO RESPIMAT. Accessed: October 21, 2020. Available at: https://www.health.gov.nl.ca/health/prescription/class_search_nl.asp?din=02441888&GReturn=GenericName&Subtitle1=Generic.

  39. Newfoundland and Labrador Health and Community Services. Drug Benefit Special Authorization – INSPIOLTO RESPIMAT. Accessed: October 21, 2020. Available at: https://www.health.gov.nl.ca/health/prescription/criteria/Tiotropium_Olodaterol_Inspiolto.pdf.

  40. NLPDP Drug Product Database – SPIRIVA RESPIMAT. Accessed: October 21, 2020. Available at: https://www.health.gov.nl.ca/health/prescription/class_search_nl.asp?din=02435381&GReturn=GenericName&Subtitle1=Generic%20or%20Brand%20
    Name%20:%20%20%20&Subtitle2=spiriva.

  41. Newfoundland and Labrador Health and Community Services. Drug Benefit Special Authorization – SPIRIVA RESPIMAT. Accessed: October 21, 2020. Available at: https://www.gov.nl.ca/hcs/files/prescription-special-auth-drug-products.pdf.

  42. Newfoundland and Labrador Health and Community Services. NLPDP Drug Product Database - COMBIVENT RESPIMAT. Accessed: December 15, 2020. Available at: https://www.health.gov.nl.ca/health/prescription/class_search_nl.asp?din=02419106&GReturn=GenericName&Subtitle1=Generic.

  43. Nova Scotia Formulary October 2020. Accessed: October 21, 2020. Available at: https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf.

  44. Non-Insured Health Benefits - First Nations and Inuit Health Branch September 2020. Accessed: October 21, 2020. Available at: https://www.sac-isc.gc.ca/DAM/DAM-ISC-SAC/DAM-HLTH/STAGING/texte-text/nihb_benefits-services_drugs_dbl-index_1573154657223_eng.pdf.

  45. Government of the Northwest Territories. Who can apply for Extended Health Benefits (EHB)? Accessed: July 19, 2021. Available at: https://www.hss.gov.nt.ca/en/services/supplementary-health-benefits/extended-health-benefits-specified-disease-conditions.

  46. Nunavut Department of Health. Extended Health Benefits (EHB) Eligible Specified Conditions. Accessed: July 19, 2021. Available at: https://www.gov.nu.ca/health/information/ehb-full-coverage-plan.

  47. Ontario Drug Benefit Formulary – Inspiolto Respimat. Accessed: October 21, 2020. Available at: https://www.formulary.health.gov.on.ca/formulary/detail.xhtml?drugId=02441888.

  48. Ontario Drug Benefit. Limited Use Notes – Inspiolto Respimat. Accessed: October 21, 2020. Available at : https://www.formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtml?pcg9Id=120808012.

  49. Ontario Drug Benefit Formulary – Spiriva Respimat. Accessed: October 21, 2020. Available at: https://www.formulary.health.gov.on.ca/formulary/detail.xhtml?drugId=02435381.

  50. Ontario Drug Benefit Formulary – Combivent Respimat. Accessed: December 15, 2020. Available at: https://www.formulary.health.gov.on.ca/formulary/detail.xhtml?drugId=02231675.

  51. PEI Pharmacare Formulary. Accessed: October 21, 2020. Available at: https://www.princeedwardisland.ca/sites/default/files/publications/
    pei_pharmacare_formulary.pdf.

  52. Quebec RAMQ List of Medications September 30, 2020. Accessed: October 21, 2020. Available at: https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste-med-2020-09-30-en.pdf.

  53. Saskatchewan Online Formulary – Inspiolto Respimat. Accessed: October 21, 2020. Available at: https://formulary.drugplan.ehealthsask.ca/SearchFormulary.

  54. Government of Saskatchewan. Appendix A Exception Drug Status Program. Accessed: October 21, 2020. Available at: https://formulary.drugplan.health.gov.sk.ca/PDFs/APPENDIXA.pdf.

  55. Government of Saskatchewan. Saskatchewan Formulary Bulletin #184. Accessed: August 9, 2022. Available at: https://formulary.drugplan.ehealthsask.ca/PDFs/Bulletin-0184-Mar-2020.pdf.

  56. Saskatchewan Online Formulary — Spiriva Respimat. Accessed: October 21, 2020. Available at: http://formulary.drugplan.ehealthsask.ca/SearchFormulary.

  57. Saskatchewan Online Formulary – Combivent Respimat. Accessed: December 15, 2020. Available at: https://formulary.drugplan.ehealthsask.ca/SearchFormulary.

  58. Yukon Drug Formulary – Inspiolto Respimat. Accessed: October 21, 2020. Available at: apps.gov.yk.ca/drugs/f?p=161:9010:361755913109089::NO:9010::&cs=31993F97DFF55F2446BDEDE93CDDCE709.

  59. Yukon Drug Formulary – Spiriva Respimat. Accessed: October 21, 2020. Available at: apps.gov.yk.ca/drugs/f?p=161:9010:361755913109089::NO:9010::&cs=31993F97DFF55F2446BDEDE93CDDCE709.

  60. Yukon Drug Formulary – Combivent Respimat. Accessed: December 15, 2020. Available at: http://apps.gov.yk.ca/drugs/f?p=161:9010:3907752167681100::NO:9010::&cs=36D95F94E25B4B83867380D6E00538934.

  61. Data on file. January 5, 2006.

  62. Bateman E, et al. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010;5:197–208.

  63. Data on File. December 10, 2021.

  64. Data on File. May 17, 2022.

  65. Data on File. July 11, 2021.

  66. Data on File. May 20, 2021.

  67. Mahler D, et al. TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow. Int J Chron Obstruct Pulmon Dis 2021;16:2455–65.

Member of Innovative Medicines Canada, Reviewed by PAAB